Bemnifosbuvir is a nucleotide analog polymerase inhibitor designed to inhibit viral replication by impairing viral RNA polymerase. It has demonstrated potent pan-genotypic antiviral activity against HCV and has shown approximately 10-fold higher activity than sofosbuvir in vitro, while retaining efficacy against sofosbuvir-resistant strains. Bemnifosbuvir’s safety profile has been favorable, with a low risk of drug-drug interactions and no food effect reported. When combined with ruzasvir, an oral NS5A inhibitor, the two compounds have shown synergistic antiviral effects in vitro. The combination of bemnifosbuvir and ruzasvir has demonstrated a high sustained virologic response rate of 98% (208/213) at 12 weeks post-treatment (SVR12) after just eight weeks of treatment in a phase II study. This regimen offers potential advantages over existing treatments, including a short treatment duration (8 weeks), low risk of drug-drug interactions, and efficacy across HCV genotypes 1-4, positioning it as a promising new option for HCV therapy. Atea’s primary patents on bemnifosbuvir, expected to expire in 2036, have been granted in 35 LMICs and are pending in another 14 LMICs. Atea owns several secondary patents on salts and polymorphs that may provide exclusivity until 2038-2042, as well as combinations with ruzasvir until 2039-2042 in many LMICs.